Home
Live Updates
Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma : vimarsana.com
Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
The FDA has approved Lunsumio (mosunetuzumab-axgb) to treat adults with R/R follicular lymphoma after 2 or more lines of systemic therapy.
Related Keywords
Roche Lunsumio ,
Elizabeth Budde ,
Drug Administration ,
Department Of Hematology Hematopoietic Cell Transplantation ,
City Of Hope Division Lymphoma ,
Boxed Warning ,
Haematologic Oncologist ,
Associate Professor ,
Hope Division ,
Hematopoietic Cell Transplantation ,
vimarsana.com © 2020. All Rights Reserved.